Niraparib as a therapeutic agent for the treatment of ovarian cancer meningeal dissemination with BRCA1 mutation.

Abstract

This study analyzed a 63-year-old woman with hereditary BRCA1 mutation. She underwent interval debulking surgery after neoadjuvant chemotherapy for high-grade serous ovarian carcinoma (HGSOC). After 2 years of postoperative chemotherapy, she developed headache and dizziness, and a suspected metastatic cerebellar mass in left ovary was detected. Pathological analysis of the mass revealed HGSOC, which was removed surgically. Eight months and another 6 months after the surgery, local recurrence was noted; hence, she underwent CyberKnife treatment. After 3 months, cervical spinal cord metastasis was found, evidenced by left shoulder pain. Moreover, meningeal dissemination was present around the cauda equina. Chemotherapy treatment, including bevacizumab, was ineffective and increased lesions were observed. After CyberKnife treatment for the cervical spinal cord metastasis, niraparib was initiated for the meningeal dissemination. The cerebellar lesions and meningeal dissemination improved within 8 months of niraparib treatment. Although meningeal dissemination is challenging to treat, niraparib may be useful in BRCA-mutated HGSOC.

• Authors: Takashi Nei, Satoshi Tamauchi, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kaoru Niimi, Hiroaki Kajiyama
• Journal: The journal of obstetrics and gynaecology research (J Obstet Gynaecol Res) Vol. 49 Issue 7 Pg. 1875-1879 (Jul 2023) ISSN: 1447-0756 [Electronic] Australia
• PMID: 37114359 (Publication Type: Case Reports)
• Copyright: © 2023 Japan Society of Obstetrics and Gynecology.

Chemical References

• niraparib
• Indazoles
• BRCA1 protein, human
• BRCA1 Protein

Topics

• Humans
• Female
• Middle Aged
• Ovarian Neoplasms (drug therapy, genetics, pathology)
• Carcinoma, Ovarian Epithelial (drug therapy)
• Indazoles (therapeutic use)
• Germ-Line Mutation
• Mutation
• BRCA1 Protein (genetics)